210 related articles for article (PubMed ID: 32227261)
1. Effect of combined colchicine-corticosteroid treatment on neutrophil/lymphocyte ratio: a predictive marker in Behçet disease activity.
Djaballah-Ider F; Touil-Boukoffa C
Inflammopharmacology; 2020 Aug; 28(4):819-829. PubMed ID: 32227261
[TBL] [Abstract][Full Text] [Related]
2. Influence of corticosteroid therapy on IL-18 and nitric oxide production during Behçet's disease.
Djaballah-Ider F; Djeraba Z; Chemli M; Dammene-Debbihe N; Lounis D; Belguendouz H; Medour Y; Chaib S; Touil-Boukoffa C
Inflammopharmacology; 2018 Jun; 26(3):725-735. PubMed ID: 29600486
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in Behçet's disease: which and when to use?
Hammad M; Shehata OZ; Abdel-Latif SM; El-Din AMM
Clin Rheumatol; 2018 Oct; 37(10):2811-2817. PubMed ID: 29980877
[TBL] [Abstract][Full Text] [Related]
4. Auto-immunity profile evaluation during different clinical manifestations of Behçet disease in Algerian patients: effect of corticosteroid treatment.
Djaballah-Ider F; Djaballah A; Djeraba Z; Chaib S; Touil-Boukoffa C
Inflammopharmacology; 2019 Dec; 27(6):1113-1122. PubMed ID: 30721371
[TBL] [Abstract][Full Text] [Related]
5. Can decreased monocyte to HDL-cholesterol ratio be a marker indicating the anti-inflammatory effect of the colchicine in Behçet's disease? A preliminary study.
Demirbaş A; Kaya İslamoğlu ZG
Dermatol Ther; 2020 Nov; 33(6):e14013. PubMed ID: 32667119
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil to lymphocyte ratio in Behçet's disease as a marker of disease activity.
Rifaioglu EN; Bülbül Şen B; Ekiz Ö; Cigdem Dogramaci A
Acta Dermatovenerol Alp Pannonica Adriat; 2014; 23(4):65-7. PubMed ID: 25527038
[TBL] [Abstract][Full Text] [Related]
7. Novel markers of endothelial dysfunction and inflammation in Behçet's disease patients with ocular involvement: epicardial fat thickness, carotid intima media thickness, serum ADMA level, and neutrophil-to-lymphocyte ratio.
Yuksel M; Yildiz A; Oylumlu M; Turkcu FM; Bilik MZ; Ekinci A; Elbey B; Tekbas E; Alan S
Clin Rheumatol; 2016 Mar; 35(3):701-8. PubMed ID: 25744156
[TBL] [Abstract][Full Text] [Related]
8. Value of hematological indices versus VEGF as biomarkers of activity in Behçet's disease.
Gheita TA; Sakr BR; Rabea RE; Abd ElHamid SM
Clin Rheumatol; 2019 Aug; 38(8):2201-2210. PubMed ID: 30919148
[TBL] [Abstract][Full Text] [Related]
9. Correlation of clinical signs and symptoms of Behçet's disease with platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR).
Shadmanfar S; Masoumi M; Davatchi F; Shahram F; Akhlaghi M; Faezi ST; Kavosi H; Parsaei A; Moradi S; Balasi J; Moqaddam ZR
Immunol Res; 2021 Aug; 69(4):363-371. PubMed ID: 34109535
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil-to-lymphocyte ratio, mean platelet volume and platelet-to-lymphocyte ratio in Behçet's disease and their correlation with disease activity: A meta-analysis.
Lee YH; Song GG
Int J Rheum Dis; 2018 Dec; 21(12):2180-2187. PubMed ID: 30417545
[TBL] [Abstract][Full Text] [Related]
11. Role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as potential biomarkers in Behçet's disease: a meta-analysis.
Lee YH; Song GG
Z Rheumatol; 2024 Feb; 83(Suppl 1):206-213. PubMed ID: 37707568
[TBL] [Abstract][Full Text] [Related]
12. Th 9 cells in Behçet disease: Possible involvement of IL-9 in pulmonary manifestations.
Kaabachi W; Khaouthar M; Hamdi B; Khalfallah I; Ammar J; Hamzaoui K; Hamzaoui A
Immunol Lett; 2019 Jul; 211():3-12. PubMed ID: 31075294
[TBL] [Abstract][Full Text] [Related]
13. Nitric Oxide, Neutrophil/Lymphocyte, and Platelet/Lymphocyte Ratios as Promising Inflammatory Biomarkers in Complicated Crohn's Disease: Outcomes of Corticosteroids and Anti-TNF-α Therapies.
Soufli I; Hablal A; Bessaad S; Amri M; Labsi M; Boussa RS; Ameur F; Belguendouz H; Younes SA; Idris NS; Touil-Boukoffa C
Inflammation; 2023 Jun; 46(3):1091-1105. PubMed ID: 36869975
[TBL] [Abstract][Full Text] [Related]
14. Increased frequencies of interleukin-2- and interferon-gamma-producing T cells in patients with active Behçet's disease.
Sugi-Ikai N; Nakazawa M; Nakamura S; Ohno S; Minami M
Invest Ophthalmol Vis Sci; 1998 May; 39(6):996-1004. PubMed ID: 9579479
[TBL] [Abstract][Full Text] [Related]
15. Colchicine modulates oxidative stress in serum and neutrophil of patients with Behçet disease through regulation of Ca²⁺ release and antioxidant system.
Korkmaz S; Erturan I; Nazıroğlu M; Uğuz AC; Ciğ B; Övey IS
J Membr Biol; 2011 Dec; 244(3):113-20. PubMed ID: 22052237
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of diagnostic performance of haematological parameters in Behçet's disease.
Tezcan D; Körez MK; Gülcemal S; Hakbilen S; Akdağ T; Yılmaz S
Int J Clin Pract; 2021 Oct; 75(10):e14638. PubMed ID: 34309974
[TBL] [Abstract][Full Text] [Related]
17. Current therapy for Behçet's disease.
Goker B; Goker H
Am J Ther; 2002; 9(5):465-70. PubMed ID: 12237740
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil/lymphocyte ratio and mean platelet volume in Behçet's disease.
Balkarli A; Kucuk A; Babur H; Erbasan F
Eur Rev Med Pharmacol Sci; 2016 Jul; 20(14):3045-50. PubMed ID: 27460734
[TBL] [Abstract][Full Text] [Related]
19. Increased nitric oxide production in patients with Behçet's disease: is it a new activity marker?
Evereklioglu C; Turkoz Y; Er H; Inaloz HS; Ozbek E; Cekmen M
J Am Acad Dermatol; 2002 Jan; 46(1):50-4. PubMed ID: 11756945
[TBL] [Abstract][Full Text] [Related]
20. The Role of Colchicine in Different Clinical Phenotypes of Behcet Disease.
Wang Z; Zu X; Xiong S; Mao R; Qiu Y; Chen B; Zeng Z; Chen M; He Y
Clin Ther; 2023 Feb; 45(2):162-176. PubMed ID: 36732153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
